Clinical Trials Directory

Trials / Completed

CompletedNCT01262586

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.

Conditions

Interventions

TypeNameDescription
DRUGVildagliptin
DRUGGlimepiride

Timeline

Start date
2010-11-01
Primary completion
2011-03-01
Completion
2011-03-01
First posted
2010-12-17
Last updated
2016-11-18

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01262586. Inclusion in this directory is not an endorsement.

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device. (NCT01262586) · Clinical Trials Directory